Brickell Biotech, Inc. (BBI)
| Market Cap | 44.96M |
| Revenue (ttm) | 337,000 |
| Net Income (ttm) | -31.85M |
| Shares Out | 68.86M |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,473,522 |
| Open | 0.527 |
| Previous Close | 0.549 |
| Day's Range | 0.515 - 0.533 |
| 52-Week Range | 0.466 - 1.700 |
| Beta | 0.36 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 11, 2021 |
About BBI
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Bou...
Financial Performance
In 2020, BBI's revenue was $1.82 million, a decrease of -76.99% compared to the previous year's $7.92 million. Losses were -$20.91 million, -12.41% less than in 2019.
Financial StatementsNews
Brickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm Sweating
Brickell Biotech Inc (NASDAQ: BBI) has announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel for primary axillary hyperhidrosis (exces...
Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary ...
Sofpironium bromide gel, 15% was generally well-tolerated
Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity
BOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative...
Brickell Biotech Acquires Rights To Candidate For Autoimmune Diseases
Brickell Biotech Inc (NASDAQ: BBI) has entered into a definitive agreement with Voronoi Inc for exclusive, worldwide rights to therapeutics generated from a proprietary DYRK1A inhibitor platform. The DY...
Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer
Dr. Luchi brings over 20 years of immunotherapeutic and drug development experience and will lead Brickell's clinical development strategy and medical affairs functions Dr. Luchi brings over 20 years of...
Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Aut...
Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022
Brickell (BBI) Reports Q2 Loss, Tops Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of -45.45% and 51.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies e...
Brickell (BBI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021
BOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...
Why Brickell Biotech Shares Are Trading Lower Today
Brickell Biotech (NASDAQ: BBI) shares are trading lower after the company announced a bought deal offering of common stock of $5 million, which was later increased to $7 million. Brickell Biotech is a c...
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and different...
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative and differe...
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollmen...
Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021 Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium B...
BOULDER, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of -25.00% and -83.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech: Q1 Earnings Insights
Shares of Brickell Biotech (NASDAQ:BBI) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.15), which m...
Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update
Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies exp...
Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescrip...
Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15...
Phase 3 Pivotal Cardigan II study exceeds 50% enrollment - - - Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021
4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now
Penny stocks on Robinhood are a big focus for Reddit traders in April The post 4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Inf...
Biotech Penny Stocks To Buy? 3 to Watch Under $5
Biotech stocks are more popular than ever; here are 3 to watch under $5 The post Biotech Penny Stocks To Buy? 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium B...
Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromi...
BOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differ...